2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

Aletaha, Daniel; Neogi, Tuhina; Silman, Alan J.; Funovits, Julia; Felson, David T.; Bingham, Clifton O.; Birnbaum, Neal S.; Burmester, Gerd R; Bykerk, Vivian P.; Cohen, Marc D.; Combe, Bernard; Costenbader, Karen H.; Dougados, Maxime; Emery, Paul; Ferraccioli, Gianfranco; Hazes, Johanna M. W.; Hobbs, Kathryn; Huizinga, Tom W J; Kavanaugh, Arthur; Kay, Jonathan; Kvien, Tore K; Laing, Timothy; Mease, Philip J.; Ménard, Henri A.; Moreland, Larry W.; Naden, Raymond L.; Pincus, Theodore; Smolen, Josef S.; Stanisławska-Biernat, Ewa; Symmons, Deborah; Tak, Paul P.; Upchurch, Katherine S.; Vencovský, Jiří; Wolfe, Frederick; Hawker, Gillian

doi:10.1136/ard.2010.138461

Cited by 3,984 publications

(2,629 citation statements)

References 24 publications

Supporting

Mentioning

2,387

Contrasting

Unclassified

100

Order By: Relevance

“…The patients fulfilled the 2010 RA classification criteria15 and had active disease as defined by disease activity score in 28 joints (DAS28) >3.2. The study was approved by the local ethics committee (Institutional Review Boards: 00008526).…”

Section: Methodsmentioning

confidence: 99%

Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis

Tournadre

Pereira

Dutheil

et al. 2017

J cachexia sarcopenia muscle

150

132

View full text Add to dashboard Cite

BackgroundRheumatoid arthritis (RA) is a chronic inflammatory disease characterized by increased mortality associated with cardiometabolic disorders including dyslipidaemia, insulin resistance, and cachectic obesity. Tumour necrosis factor inhibitors and interleukin 6 receptor blocker licensed for the treatment of RA decrease inflammation and could thus improve cardiovascular risk, but their effects on body composition and metabolic profile need to be clarified. We investigated the effects of tocilizumab (TCZ), a humanized anti‐interleukin 6 receptor antibody, on body composition and metabolic profile in patients treated for RA.MethodsTwenty‐one active RA patients treated with TCZ were included in a 1 year open follow‐up study. Waist circumference, body mass index, blood pressure, lipid profile, fasting glucose, insulin, serum levels of adipokines and pancreatic/gastrointestinal hormones, and body composition (dual‐energy X‐ray absorptiometry) were measured at baseline and 6 and 12 months of treatment. At baseline, RA patients were compared with 21 non‐RA controls matched for age, sex, body mass index, and metabolic syndrome.ResultsCompared with controls, body composition was altered in RA with a decrease in total and appendicular lean mass, whereas fat composition was not modified. Among RA patients, 28.6% had a skeletal muscle mass index below the cut‐off point for sarcopaenia (4.8% of controls). After 1 year of treatment with TCZ, there was a significant weight gain without changes for fat mass. In contrast, an increase in lean mass was observed with a significant gain in appendicular lean mass and skeletal muscle mass index between 6 and 12 months. Distribution of the fat was modified with a decrease in trunk/peripheral fat ratio and an increase in subcutaneous adipose tissue. No changes for waist circumference, blood pressure, fasting glucose, and atherogenic index were observed.ConclusionsDespite weight gain during treatment with TCZ, no increase in fat but a modification in fat distribution was observed. In contrast, muscle gain suggests that blocking IL‐6 might be efficient in treating sarcopaenia associated with RA.

show abstract

Section: Methodsmentioning

confidence: 99%

Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis

Tournadre

Pereira

Dutheil

et al. 2017

J cachexia sarcopenia muscle

150

132

View full text Add to dashboard Cite

show abstract

“…All patients fulfilled the (ACR) classification criteria for RA [14]. There was no significant difference in biomarkers levels between pre- and post-menopausal women.…”

Section: Methodsmentioning

confidence: 99%

A cross sectional study of bone and cartilage biomarkers: correlation with structural damage in rheumatoid arthritis

Achour

Bouaziz

Mechri

et al. 2018

Libyan Journal of Medicine

View full text Add to dashboard Cite

The aim of our study was to assess the relationship between bone and cartilage remodeling biomarkers and joint damage in Rheumatoid Arthritis (RA), and to detect whether they have the capacity to predict the progression of joint disease assessment by computed tomography (CT) erosion score. We analyzed 65 female patients with established RA in our Rheumatology Department. Serum levels of bone and cartilage markers were measured: osteocalcin (OC), N-propeptide of type I collagen (PINP), collagen type I and II, C-telopeptide (CTX I, CTX-II) and cartilage oligomeric matrix protein (COMP). Radiography of both wrist and MCP joints were available. Two expert-readers independently scored articular damage and progression using the High-resolution low dose CT scan in a blinded fashion. 65 female patients with established RA with a median age of 44 years were included. The median disease-duration was two years and the median (Disease activity score) DAS 28 score at 4.46 [2.65–7.36]. The percentage of patient with low disease activity was 13.8%, while 55.4 and 30.8% for those with moderate and high disease activity respectively. The resorption bone markers were high in active versus non-active RA. Wrist and MCP erosion scores were also associated with RA activity. Our study shows that biomarkers of bone and cartilage collagen breakdown were related to specific joint erosion in RA and could predict subsequent radiographic damage in RA. Further larger scale longitudinal studies maybe needed to confirm our data.

show abstract

“…We used a self-reported questionnaire to collect baseline data on demographic characteristics (age, sex, ever smoker, education status, occupational category), time to see a rheumatologist (delay between the first symptom and the first visit to a rheumatologist), disease characteristics (Disease Activity Score in 28 (31,32).…”

Section: Patient Characteristicsmentioning

confidence: 99%

Work Productivity Loss in Early Arthritis During the First 3 Years of Disease: A Study From a French National Multicenter Cohort

Dadoun

Guillemin

Lucier³

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To assess work productivity (WP) loss during the first 3 years of disease in a cohort of patients with early arthritis (EA) diagnosed between 2002 and 2005. Methods. The ESPOIR (Etude et Suivi des Polyarthrites Indifférenciées Récentes) cohort included 813 EA patients; we included those of working age at baseline in the present study. WP loss was assessed by 3 components: sick leave, permanent disability, and early retirement. The proportion of affected patients and the mean number of days off work were assessed for each component. WP costs were estimated and determinants of positive and extreme costs were assessed by logistic regression models. Results. Among the 664 patients included, 81.6% were in the workforce at baseline. During the first 3 years of disease, 45% reported at least 1 sick leave day and 11% reported permanent disability. Only a few patients (1%) reported early retirement. The mean number of days on sick leave due to EA decreased regularly from 44 to 13, whereas the mean number of days on permanent disability tripled from 10 to 33. The mean annual cost was €1,333 (95% confidence interval €1,075-1,620). Sick leave longer than 30 days due to EA before inclusion and a decrease in mental and physical scores of the Medical Outcomes Study Short Form 36 at inclusion were independent determinants of positive and extreme costs in multivariate models. Conclusion. WP loss is substantial in EA patients and is due to permanent disability before the third year of disease. Work absence and poor mental and physical health status at baseline are major determinants of WP costs.

show abstract

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

Cited by 3,984 publications

References 24 publications

Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis

Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis

A cross sectional study of bone and cartilage biomarkers: correlation with structural damage in rheumatoid arthritis

Work Productivity Loss in Early Arthritis During the First 3 Years of Disease: A Study From a French National Multicenter Cohort

Contact Info

Product

Resources

About